|
Sex (percentage female)
|
48 (87.3)
|
9 (64.2)
|
0.01
|
|
Age (years)
|
39.1 ± 12.4
|
39.9 ± 10.7
|
0.3
|
|
BMI (kg/m2)
|
22.4 ± 3.3
|
20.9 ± 2.3
|
0.5
|
|
Systolic blood pressure (mmHg)
|
127.8 ± 17.0
|
136.4 ± 21.5
|
0.2
|
|
Diastolic blood pressure
|
79.7 ± 13.6
|
83.6 ± 14.5
|
0.3
|
|
Disease duration (years)
|
5.1 ± 6.8
|
8.0 ± 6.4
|
0.4
|
|
SLEDAI
|
15.6 ± 4.8
|
13.0 ± 4.8
|
0.4
|
|
SDI
|
0.4 ± 0.6
|
0.6 ± 0.8
|
0.7
|
|
Proteinuria (g/gCr)
|
2.7 ± 2.1
|
3.7 ± 1.8
|
0.07
|
|
eGFR (mL/min)
|
76.6 ± 28.2
|
72.2 ± 32.8
|
0.9
|
|
Anti-dsDNA antibody (IU/mL)
|
177 ± 274
|
112 ± 116
|
0.6
|
|
Anti-cardiolipin antibody (IU/mL)
|
21.8 ± 30.7
|
14.7 ± 28.5
|
0.5
|
|
Lupus anticoagulant-positive (%)
|
3 (5.5)
|
1 (7.1)
|
0.6
|
|
CH50 (U/ml)
|
17.1 ± 9.3
|
24.4 ± 14.2
|
0.06
|
|
Prednisolone (mg/day)
|
45.5 ± 15.1
|
37.1 ± 10.1
|
0.08
|
|
Induction therapy
|
|
IVCY (%)
|
29 (52.7)
|
5 (35.7)
|
0.4
|
|
MMF (%)
|
8 (14.5)
|
2 (14.3)
|
0.9
|
|
Tacrolimus (%)
|
8 (14.5)
|
2 (14.3)
|
0.9
|
|
PSL monotherapy (%)
|
6 (10.9)
|
2 (14.3)
|
0.8
|
|
Others (%)
|
4 (7.3)
|
3 (21.4)
|
0.1
|
|
Renal pathological findings
|
|
ISN/RPS classification
|
|
III or III + V (%)
|
26 (47.3)
|
5 (35.7)
|
0.4
|
|
IV or IV + V (%)
|
29 (52.7)
|
9 (64.3)
|
0.4
|
|
Endocapillary hypercellularity (%)
|
39.2 ± 18.6
|
46.0 ± 30.2
|
0.5
|
|
Leukocyte infiltration (%)
|
2.0 ± 4.9
|
2.2 ± 4.1
|
0.4
|
|
Subendothelial hyaline deposits (%)
|
29.1 ± 30.2
|
30.1 ± 28.9
|
0.3
|
|
Fibrinoid necrosis/karyorrhexis (%)
|
7.0 ± 11.1
|
8.1 ± 18.1
|
0.3
|
|
Cellular crescents (%)
|
7.0 ± 11.1
|
8.1 ± 18.1
|
0.7
|
|
Interstitial inflammation (%)
|
2.1 ± 3.7
|
2.3 ± 7.4
|
0.5
|
|
Glomerular sclerosis (%)
|
2.5 ± 7.1
|
3.9 ± 8.2
|
0.4
|
|
Fibrous crescents (%)
|
2.1 ± 2.0
|
2.2 ± 3.1
|
0.7
|
|
Tubular atrophy (%)
|
2.8 ± 4.7
|
3.3 ± 5.9
|
0.5
|
|
Interstitial fibrosis (%)
|
4.7 ± 6.8
|
5.1 ± 5.9
|
0.6
|
|
Activity index
|
5.2 ± 3.0
|
5.1 ± 3.8
|
0.5
|
|
Chronicity index
|
1.4 ± 0.4
|
1.4 ± 1.3
|
0.7
|
